Attached files
| file | filename |
|---|---|
| EX-99.3 - Protagenic Therapeutics, Inc.\new | ex99-3.htm |
| EX-99.2 - Protagenic Therapeutics, Inc.\new | ex99-2.htm |
| EX-99.1 - Protagenic Therapeutics, Inc.\new | ex99-1.htm |
| EX-32.1 - Protagenic Therapeutics, Inc.\new | ex32-1.htm |
| EX-31.2 - Protagenic Therapeutics, Inc.\new | ex31-2.htm |
| EX-31.1 - Protagenic Therapeutics, Inc.\new | ex31-1.htm |
| EX-21.1 - Protagenic Therapeutics, Inc.\new | ex21-1.htm |
| EX-10.4 - Protagenic Therapeutics, Inc.\new | ex10-4.htm |
| EX-10.2 - Protagenic Therapeutics, Inc.\new | ex10-2.htm |
| 10-K - Protagenic Therapeutics, Inc.\new | form10-k.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the Registration Statement on Forms S-8 (File Nos. 333-214553, 333-214554, 333-217963, 333-232535, 333-237081, 333-254112) of our report dated March 23, 2021 with respect to the consolidated financial statements of Protagenic Therapeutics, Inc. (the “Company”) appearing in this Annual Report on Form 10-K for the year ended December 31, 2020. Our report contains an explanatory paragraph regarding the Company’s ability to continue as a going concern.
| /s/ MaloneBailey, LLP | |
| www.malonebailey.com | |
| Houston, Texas | |
| March 23, 2021 |